EBITDA: Income before interest, taxes, depreciation and amortization.
VYNE Therapeutics Inc. (VYNE) had EBITDA of $-30.50M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$0.57M |
|
$-26.48M |
|
-- |
|
$0.57M |
|
$30.32M |
|
$-29.75M |
|
$3.02M |
|
$-26.73M |
|
$-26.73M |
|
$-26.74M |
|
$-26.74M |
|
$-26.48M |
|
$-26.74M |
|
$-29.75M |
|
|
EBITDA |
$-30.50M |
42.77M |
|
42.77M |
|
$-0.62 |
|
$-0.62 |
|
| Balance Sheet Financials | |
$30.01M |
|
$0.09M |
|
$0.15M |
|
$30.16M |
|
$2.40M |
|
-- |
|
-- |
|
$2.40M |
|
$27.77M |
|
$27.77M |
|
$27.77M |
|
33.32M |
|
| Cash Flow Statement Financials | |
$-33.12M |
|
$37.37M |
|
$-0.14M |
|
$19.93M |
|
$24.03M |
|
$4.10M |
|
$2.31M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
12.53 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-5219.12% |
|
-5219.12% |
|
-5351.58% |
|
-4689.82% |
|
-4646.14% |
|
$-33.12M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
-- |
|
-- |
|
-96.29% |
|
-96.29% |
|
-88.65% |
|
-96.29% |
|
$0.83 |
|
$-0.77 |
|
$-0.77 |
|